Ticker Symbol: NVCR
NovoCure Ltd
$109.49 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
Jersey
Currency:
USD
Asset
Type: Common Stock
CIK:0001645113
Company Profile
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Standard Industrial Classification Code (SIC code): 3841
Address: Forum
Website: www.novocure.com
CEO: Asaf Danziger
Tags:
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $15.30
Change:
-$0.28
(
-1.86%)
Days Range: $15.25 - $15.72
Beta: 0.70
52wk. High: $120.03
52wk. Low: $13.46
Ytd. Change -80.61%
50 Day Moving Average: $17.21
200 Day Moving Average: $42.13
Shares Outstanding: 106615874
Valuation
Market Cap: 163.1B
PE Ratio: -9.27
EPS (TTM): -1.65
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A